Jimmy Fund Press Releases
Boston magazine has named 51 physicians and surgeons affiliated with Dana-Farber Cancer Institute to its annual Top Doctors guide.
The Pan-Mass Challenge (PMC) today announced a gift of $47 million to support adult and pediatric patient care and cancer research at Dana-Farber.
Ovarian cancer science - "This is an exciting time for those of us engaged in research and patient care for ovarian cancer."
William G. Kaelin Jr., MD, Dana-Farber researcher, awarded 2016 Lasker Award for Basic Medical ResearchSeptember 13, 2016
William G. Kaelin Jr., MD, Dana-Farber researcher, awarded 2016 Lasker Award for Basic Medical Research. The Lasker Award is America's most prestigious biomedical award.
U.S. News & World Report names Dana-Farber/Brigham and Women's Cancer Center the best in the region in cancerAugust 02, 2016
U.S. News & World Report names Dana-Farber/Brigham and Women's Cancer Center the best in the region in cancer.
U.S. News & World Report has once again named Dana-Farber/Boston Children's Cancer and Blood Disorders Center the nation's #1 pediatric cancer program in its new 2016-17 Best Children's Hospitals rankings.
As one of the hottest topics in cancer research today, immunotherapy and Dana-Farber took center stage at the 2016 American Society of Clinical Oncology meeting in Chicago.
Dual stem-cell transplant improves outlook for children with high-risk neuroblastoma, according to a clinical trial.
New cancer immunotherapy approach combines tumor fighting power with fewer side effects, study showsMay 16, 2016
Basic research into the dual nature of certain immune system cells has set the stage for a new approach to cancer immunotherapy.
Dana-Farber Cancer Institute has been named to Becker's Hospital Review’s 2016 list of "100 Great Hospitals in America."
Dana-Farber and Fitbit announced a partnership to support a potentially ground-breaking study that investigates the impact of weight loss on breast cancer recurrence.
Dana-Farber Cancer Institute today appointed Larry Lucchino as Chairman of the Jimmy Fund.
FDA approval of the new drug Defibrotide brightens the outlook for stem cell transplant patients.
Laurie H. Glimcher, MD, an internationally recognized immunologist, has been named the next president and CEO of Dana-Farber Cancer Institute.
Dana-Farber Cancer Institute and Lifespan Health System will form a partnership in Rhode Island. The shared goal is to advance cancer care in the region.
Researchers found a way of differentiating rare pediatric brain tumors and developed a pathological test that will help children avoid unnecessary and potentially damaging additional therapies.
Dana-Farber Cancer Institute scientists discover an important genetic source of human diversity.
The Resolution by PMC, the first indoor cycling event from the Pan-Mass Challenge (PMC), was held at The Club by George Foreman III in the Seaport District on January 2 and 3.
New treatments for leukemia, colorectal cancer, brain cancer, lung cancer and breast cancer topped the list of most important research and clinical developments at Dana-Farber in 2015.